Jing Hua, Miaomiao Chu, Chaohui Wang, Hangfan Zhang, Jing Luan, Yifei Zhang, Qiang Li, Taiwu Xiao, Chuansheng Zhu, Xuan Li, Bo Fu
{"title":"Digital PCR-based <i>GRHL2</i> methylation testing in acute myeloid leukemia: diagnosis, prognosis and monitoring.","authors":"Jing Hua, Miaomiao Chu, Chaohui Wang, Hangfan Zhang, Jing Luan, Yifei Zhang, Qiang Li, Taiwu Xiao, Chuansheng Zhu, Xuan Li, Bo Fu","doi":"10.2217/epi-2023-0406","DOIUrl":null,"url":null,"abstract":"<p><p><b>Background:</b> Acute myeloid leukemia (AML) is a challenging disease with high rates of recurrence. The role of the cancer-related gene <i>GRHL2</i> in AML has not been widely studied. <b>Methods:</b> Peripheral blood samples were collected from 73 AML patients and 68 healthy controls. Droplet digital PCR was used to detect <i>GRHL2</i> methylation levels to explore the value of <i>GRHL2</i> methylation in the diagnosis, treatment response and prognosis of AML. <b>Result:</b> <i>GRHL2</i> methylation was significantly increased in AML patients (p < 0.01), with high diagnostic accuracy (area under the curve: 0.848; p < 0.001). <i>GRHL2</i> methylation was correlated with chemotherapy response (p < 0.05) and is an independent prognostic factor for AML (p < 0.05). <b>Conclusion:</b> <i>GRHL2</i> methylation is expected to serve as a biomarker for diagnosing AML patients and predicting prognosis.</p>","PeriodicalId":11959,"journal":{"name":"Epigenomics","volume":" ","pages":"233-247"},"PeriodicalIF":3.0000,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Epigenomics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2217/epi-2023-0406","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/2/12 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Acute myeloid leukemia (AML) is a challenging disease with high rates of recurrence. The role of the cancer-related gene GRHL2 in AML has not been widely studied. Methods: Peripheral blood samples were collected from 73 AML patients and 68 healthy controls. Droplet digital PCR was used to detect GRHL2 methylation levels to explore the value of GRHL2 methylation in the diagnosis, treatment response and prognosis of AML. Result:GRHL2 methylation was significantly increased in AML patients (p < 0.01), with high diagnostic accuracy (area under the curve: 0.848; p < 0.001). GRHL2 methylation was correlated with chemotherapy response (p < 0.05) and is an independent prognostic factor for AML (p < 0.05). Conclusion:GRHL2 methylation is expected to serve as a biomarker for diagnosing AML patients and predicting prognosis.
期刊介绍：
Epigenomics provides the forum to address the rapidly progressing research developments in this ever-expanding field; to report on the major challenges ahead and critical advances that are propelling the science forward. The journal delivers this information in concise, at-a-glance article formats – invaluable to a time constrained community.
Substantial developments in our current knowledge and understanding of genomics and epigenetics are constantly being made, yet this field is still in its infancy. Epigenomics provides a critical overview of the latest and most significant advances as they unfold and explores their potential application in the clinical setting.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
